Risk factors for fragility fractures in patients with immunobullous diseases on long-term systemic glucocorticoids.
作者信息
May Liau MeiQi, Chandran Nisha Suyien
机构信息
Division of Dermatology, National University of Singapore (NUHS), Singapore.
出版信息
Dermatol Reports. 2024 Mar 4;16(3):9813. doi: 10.4081/dr.2024.9813. eCollection 2024 Sep 2.
Abstract
摘要
相似文献
1
Risk factors for fragility fractures in patients with immunobullous diseases on long-term systemic glucocorticoids.长期接受全身糖皮质激素治疗的免疫性大疱性疾病患者发生脆性骨折的危险因素。
Dermatol Reports. 2024 Mar 4;16(3):9813. doi: 10.4081/dr.2024.9813. eCollection 2024 Sep 2.
2
Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.阿仑膦酸钠预防自身免疫性大疱性疾病中糖皮质激素诱导的骨质疏松：一项随机、双盲、安慰剂对照研究。
Arch Dermatol. 2012 Mar;148(3):307-14. doi: 10.1001/archdermatol.2011.354. Epub 2011 Nov 21.
3
Pneumocystis pneumonia in patients with immunobullous dermatoses.免疫性大疱性皮肤病患者的肺孢子菌肺炎。
Int J Dermatol. 2011 Sep;50(9):1144-9. doi: 10.1111/j.1365-4632.2010.04857.x.
4
Fracture risk in systemic lupus erythematosus patients over 28 years.系统性红斑狼疮患者 28 年以上的骨折风险。
Rheumatology (Oxford). 2021 Jun 18;60(6):2765-2772. doi: 10.1093/rheumatology/keaa705.
5
Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sjögren syndrome.原发性干燥综合征患者的骨质疏松症和脆性骨折的患病率及相关因素。
Rheumatol Int. 2020 Aug;40(8):1259-1265. doi: 10.1007/s00296-020-04615-3. Epub 2020 Jun 12.
6
Incidence of osteoporosis and fragility fractures in asthma: a UK population-based matched cohort study.哮喘患者骨质疏松症和脆性骨折的发生率：一项基于英国人群的匹配队列研究。
Eur Respir J. 2021 Jan 21;57(1). doi: 10.1183/13993003.01251-2020. Print 2021 Jan.
7
Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary diseases.识别并治疗肺部疾病患者的糖皮质激素性骨质疏松症。
Chest. 2004 May;125(5):1859-76. doi: 10.1378/chest.125.5.1859.
8
Osteoporosis in health and disease: a dermatologist's perspective.
Dermatol Clin. 2006 Apr;24(2):241-9, vii. doi: 10.1016/j.det.2006.01.013.
9
Glucocorticoid-induced osteoporosis in dermatologic practice: a review.皮肤科实践中的糖皮质激素性骨质疏松症：综述
J Drugs Dermatol. 2008 Nov;7(11):1053-9.
10
Fragility Fracture: 10 Commandments.脆性骨折：十条戒律。
Indian J Orthop. 2025 Mar 27;59(3):244-255. doi: 10.1007/s43465-025-01356-y. eCollection 2025 Mar.
本文引用的文献
1
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.2017 年美国风湿病学会糖皮质激素诱导性骨质疏松症预防和治疗指南。
Arthritis Rheumatol. 2017 Aug;69(8):1521-1537. doi: 10.1002/art.40137. Epub 2017 Jun 6.
2
Bisphosphonates for steroid-induced osteoporosis.双膦酸盐用于治疗类固醇诱导的骨质疏松症。
Cochrane Database Syst Rev. 2016 Oct 5;10(10):CD001347. doi: 10.1002/14651858.CD001347.pub2.
3
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.长期双膦酸盐治疗患者的骨质疏松管理：美国骨与矿物质研究学会特别工作组报告
J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708.
4
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.双膦酸盐类药物与转子下、股骨干和非典型股骨骨折风险：系统评价和荟萃分析。
J Bone Miner Res. 2013 Aug;28(8):1729-37. doi: 10.1002/jbmr.1893.
5
Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.阿仑膦酸钠预防自身免疫性大疱性疾病中糖皮质激素诱导的骨质疏松：一项随机、双盲、安慰剂对照研究。
Arch Dermatol. 2012 Mar;148(3):307-14. doi: 10.1001/archdermatol.2011.354. Epub 2011 Nov 21.
6
Calcium and vitamin D for corticosteroid-induced osteoporosis.钙和维生素D用于治疗皮质类固醇诱导的骨质疏松症。
Cochrane Database Syst Rev. 2000;1998(2):CD000952. doi: 10.1002/14651858.CD000952.
Zotero 插件